Gufic Biosciences gets DCGI nod for Thymosin Alpha-1

05 Apr 2022 Evaluate

Gufic Biosciences has received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients requiring ventilator support (NIV as well as Mechanical Ventilation). Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19.

Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.

Gufic Biosciences Share Price

347.25 -4.20 (-1.20%)
17-Dec-2025 12:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.90
Dr. Reddys Lab 1276.50
Cipla 1493.05
Zydus Lifesciences 918.85
Lupin 2115.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×